Diligence memo · auto-generated · as of July 2, 2026
Paulex Bio Inc.
Paulex Bio Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Paulex Bio Inc. operates in Pharmaceuticals, based in LA JOLLA.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Paulex Bio Inc. has raised $19M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $19M on 2025-11-21.
Most recent recorded round closed around 2025-11-21.
Valuation (modeled)modeled
Provath models Paulex Bio Inc. at approximately $75M (range $39M–$103M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.67× the median modeled value of Series B Pharmaceuticals companies in 2025–2027 (17 peers) — value vs value, same stage and era. Within the normal band (67% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 7 mo ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 65% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 50% of those peers.
Closest niche peers: Phlow Corp., AlphaTON Capital Corp, Triton Therapeutics, Inc., Sensorium Therapeutics, Inc., Belhaven Biopharma Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.